Veradermics (MANE) Free Cash Flow (2025 - 2026)
Veradermics (MANE) posted Free Cash Flow of -$21.4 million for Q1 2026, down 60.48% on a QoQ basis from -$13.3 million in Q1 2025, and down 60.48% year-over-year from -$54.1 million in Q1 2025.
Veradermics (MANE) Free Cash Flow (2025 - 2026) Analysis & Trends
Veradermics' Free Cash Flow history runs 2 years deep, the most recent figure standing at -$21.4 million for Q1 2026.
- Quarterly Free Cash Flow fell 60.48% year-over-year to -$21.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.7 million (changed N/A YoY) and the FY2025 annual result came in at -$71.6 million, down 202.37% from the prior year.
- Free Cash Flow was -$21.4 million for Q1 2026 at Veradermics, down from -$13.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$13.3 million in Q1 2025 and bottomed at -$21.4 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Veradermics | 2.63 Bn | 2.63 Bn | - | -21.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.37 Mn |
| Mar 31, 2026 | -21.37 Mn |
| Mar 31, 2025 | -13.32 Mn |
| Mar 31, 2025 | -13.32 Mn |